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Introduction: EGFR-mutant lung cancers are sensitive to EGFR
tyrosine kinase inhibitors (TKIs). Unfortunately, they develop resis-
tance, often due to acquisition of a second-site mutation (T790M).
Current EGFR TKIs select for T790M in preclinical models of
acquired resistance. We explored whether all EGFR TKIs similarly
select for the T790M mutation using data from early clinical trials
and established in vitro models of acquired resistance.
Methods: We analyzed the clinical characteristics of eight patients
with metastatic EGFR-mutant lung adenocarcinoma who were treated
first-line with XL647 and then progressed. XL647 is an ATP-compet-
itive inhibitor of EGFR, HER2, KDR, and EPHB4. Additional molec-
ular preclinical studies were performed to characterize resistance.
Results: Four patients displayed confirmed partial responses (PRs),
three patients had unconfirmed PRs, and one patient displayed stable
disease. Only one of five patients’ tumor samples available for
analysis after disease progression harbored the T790M mutation.
Eight patients subsequently received erlotinib, with (n  3) or
without (n  5) chemotherapy. Three of five patients treated with
single-agent erlotinib derived additional benefit, staying on drug up
to 9 months. EGFR-mutant PC-9 cells with acquired resistance to
XL647 did not harbor the T790M mutation, displayed a distinct
mRNA profile from PC-9 cells with T790M-mediated resistance,
and were moderately sensitive to erlotinib in growth inhibition
assays. Crystal structure analyses of XL647/EGFR T790M did not
reveal a different binding mode from that of erlotinib.
Conclusions: The findings of this exploratory study suggest that
different EGFR TKIs may select for distinct mechanisms of resistance.
These results raise the possibility that different EGFR TKIs could be
sequentially used to improve outcomes in patients with EGFR-mutant
lung cancer. Further work investigating this hypothesis is warranted.
Key Words: Non-small cell lung cancer, EGFR mutations, XL647,
EGFR tyrosine kinase inhibitors, Acquired resistance, Gefitinib,
Erlotinib, Afatinib.
(J Thorac Oncol. 2012;7: 434–442)
Mutations within the gene encoding the epidermal growthfactor receptor (EGFR) are found in a subset of non-
small cell lung cancer (NSCLC) patients. Particular muta-
tions, such as deletions in exon 19 (19 del) and point muta-
tions in exon 21 (L858R), are associated with high sensitivity
to the tyrosine kinase inhibitors (TKIs) gefitinib and erlo-
tinib.1–3 Unfortunately, acquired resistance to these agents
occurs after approximately 1 year.4,5 The most common
mechanism of resistance involves a second-site mutation
within EGFR, i.e., T790M. This change restores receptor
affinity for its natural substrate, ATP, versus drug.6–8 The
T790M mutation is rarely found in TKI-naive samples but is
observed in 50% of tumors with acquired resistance to
erlotinib or gefitinib.9,10
Multiple “second-generation” inhibitors have been de-
veloped to overcome T790M-mediated resistance.10 Irrevers-
ible EGFR inhibitors, such as neratinib (HKI-272), da-
comitinib (PF 00299804), and afatinib (BIBW-2992), bind
covalently to the receptor and are more potent in vitro against
T790M than gefitinib or erlotinib.11–13 However, continuous
exposure of EGFR-mutant lung adenocarcinomas cells in
vitro to these agents still leads to the resistance mediated by
T790M.9,14,15 In patients, the clinical activity of neratinib and
afatinib against T790M-harboring tumors has been disap-
pointing, possibly because of an inability to achieve high
enough plasma concentrations to inhibit the double mutant
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receptor without significant toxicity.16,17 The activity of da-
cominitib in this patient population remains to be established.
XL647 is a distinct “second-generation” small-mole-
cule inhibitor of EGFR (IC50 0.3 nM). The compound is a
reversible ATP-competitive TKI that also potently inhibits
ERBB2 (16 nM), KDR (1.5 nM), and EPHB4 (1.4 nM).18
Preclinical studies showed efficacy against EGFR-driven tu-
mors, including potentially those harboring T790M.18 How-
ever, in a phase II trial for NSCLC patients that displayed
acquired resistance to gefitinib or erlotinib, XL647 induced
only a 3% response rate, and patients with confirmed T790M-
harboring tumors had worse progression-free survival.19
Thus, the efficacy of this agent in the setting of acquired
resistance was also discouraging.
Concurrently, a separate phase II trial of first-line
treatment with XL647 in patients who met defined clinical
criteria (i.e., lung adenocarcinoma, never-smokers, females,
documented EGFR mutation) was performed. Although the
radiographic response rate in the overall population was 19.6%,
8 of 14 (57%) patients with EGFR-mutant tumors displayed
significant tumor shrinkage (confirmed partial [PR] or complete
response.19 These clinical data demonstrate that EGFR TKI-
naive tumors with drug-sensitive (19 del and L858R) EGFR
mutations are highly sensitive to treatment with XL647. In this
exploratory study, we investigated mechanisms of disease pro-
gression on XL647 in patients with EGFR-mutant tumors and in
relevant preclinical models.
PATIENTS AND METHODS
Patients
Trial enrollment was limited to patients with histolog-
ically confirmed diagnosis of stage IIIB or IV adenocarci-
noma and either a documented EGFR mutation or at least one
of the following clinical criteria: Asian, female, minimal
smoking history (15 pack-year smoking history and no
smoking within the previous 25 years), or no smoking his-
tory. Tumor responses were assessed as per the Response
Evaluation Criteria in Solid Tumors (RECIST).20 For com-
plete details of the trial see Pietanza et al.19 Patients at
Memorial Sloan-Kettering Cancer Center (MSKCC) were
rebiopsied with consent on an IRB-approved protocol (#04-
103). Among the eight total patients in the phase II study with
EGFR-mutant tumors who displayed confirmed PRs, two
were at an outside institution, one remains on study, and one
patient came off XL647 after response but before disease
progression because of toxicity. These patients were therefore
not studied further. Four additional patients on the study with
EGFR-mutant tumors at MSKCC were studied, including
three with unconfirmed PRs and one with stable disease.
Derivation and Characterization of
TKI-Resistant Cell Lines
Resistant cells were derived using established proto-
cols.9 Cells were deemed resistant when they could grow in
1 M XL647.
Immunoblotting
Immunoblotting and phospho-receptor tyrosine kinase
arrays were performed as per standard protocols.9
Molecular Characterization of Tumor Cell DNA
and Resistant Cells
Direct dideoxynucleotide-based sequencing and poly-
merase chain reaction-restriction fragment length polymor-
phisms were performed as per standard protocols.7,9 Addi-
tional multiplex mutational profiling was performed as
published.21 MET fluorescence in situ hybridization (FISH)
was performed as per standard protocols.22 Array compara-
tive genomic hybridization was performed as previously
described.23
For microarray experiments, RNA was extracted from
sensitive and resistant cells in the presence and absence of
TKI, as previously described.24 Microarray profiling was
performed using U133 Plus chips (Affymetrix). Microarray
data were normalized using the Robust MultiChip Averaging
algorithm as implemented in the Bioconductor package
Affy.25 The gene expression values were transformed to log2
scale. The moderated t-statistic implemented in the Biocon-
ductor LIMMA package was used to detect differentially
expressed probe sets between PC-9/XL-R and PC-9/ER 
PC-9/BR. This statistic has the same interpretation as the
standard t-statistic; however, the standard errors were calcu-
lated to shrink toward a common value by the empirical
Bayes model to borrow information across all genes.26 To
control for false discovery rates, p values for moderated t
tests were adjusted using the method of Benjamini and
Hochberg.27 For heatmap generation, 28,088 probes with
absolute beta coefficients greater than 1.5 were selected (in
the LIMMA model comparing PC-9/XL-R and PC-9/ER 
PC-9/BR groups). For hierarchical clustering, complete link-
age and Euclidean distance were used.
Crystal Structure Analysis
The crystal structures of both the Apo form of the
gatekeeper mutant of EGFR (T790M) at 2.7 Å resolution and
also its complex with XL647 at 2.3 Å resolution were solved.
Crystals of the Apo form of EGFR-T790M were prepared
using protein purified from more than 90 liters of expression
media into which XL647 was soaked.
RESULTS
Characterization of EGFR-Mutant Tumors from
Patients Treated with XL647
We studied in detail the clinical course of eight patients
with EGFR-mutant lung cancer who were treated at MSKCC
with first-line XL647 but then progressed on treatment (Table
1). All patients had tumors harboring either 19 dels or L858R.
Five patients were treated on a 5-day on, 9-day off schedule
(350 mg PO once a day), while three were treated with daily
dosing (300 mg PO once a day). Four patients displayed
confirmed PRs, three patients had unconfirmed PRs, and one
had stable disease. The median time on drug was 7 months
(range, 4–19 months). Only one of five (20%) patients’ tumor
samples available for analysis after disease progression har-
bored the T790M mutation; this patient underwent dose
reduction from 300 mg PO once a day to 200 mg PO once a
day due to toxicity and had only an unconfirmed PR. All
rebiopsied tumors showed adenocarcinoma histology. Upon
Journal of Thoracic Oncology • Volume 7, Number 2, February 2012 EGFR-Mutant Lung Adenocarcinomas
Copyright © 2012 by the International Association for the Study of Lung Cancer 435
TA
B
LE
1.
C
ha
ra
ct
er
is
tic
s
of
Ei
gh
t
Pa
tie
nt
s
at
M
SK
C
C
w
ith
D
ru
g-
Se
ns
iti
ve
EG
FR
-M
ut
an
t
Lu
ng
A
de
no
ca
rc
in
om
as
Tr
ea
te
d
w
ith
X
L6
47
ID
T
re
at
m
en
t
w
it
h
X
L
64
7
B
io
ps
ie
s
G
en
ot
yp
e
T
re
at
m
en
t
w
it
h
E
rl
ot
in
ib
D
os
in
g
Sc
he
du
le
B
es
t
R
es
po
ns
e
T
im
e
on
D
ru
g
(m
o)
Si
te
a
H
is
to
lo
gy
P
ri
m
ar
y
M
ut
n
Se
co
nd
ar
y
M
ut
n
M
E
T
A
m
p
C
lin
ic
al
B
en
efi
t
fr
om
E
rl
ot
in
ib
Si
ng
le
A
ge
nt
or
w
it
h
C
he
m
ot
he
ra
py
T
im
e
on
D
ru
g
(m
o)
1
5d
on
,
9d
of
f
P
R
19
P
re
-
R
.
pl
eu
ra
A
de
no
19
de
l
N
/A
N
/A
N
o
S
in
gl
e
ag
en
t
2
P
os
t-
N
/A
N
/A
2
5d
on
,
9d
of
f
P
R
9
P
re
-
L
.
lu
ng
m
as
s
A
de
no
19
de
l
N
on
e
N
o
Y
es
S
in
gl
e
ag
en
t
9
P
os
t-
L
.
pl
eu
ra
A
de
no
3
5d
on
,
9d
of
f
P
R
6
P
re
-
L
2
ve
rt
eb
ra
A
de
no
19
de
l
N
on
e
N
/A
Y
es
W
it
h
ch
em
ot
he
ra
py
7
P
os
t-
L
.
si
xt
h
ri
b
A
de
no
4
5d
on
,
9d
of
f
uP
R
5
P
re
-
R
.
pl
eu
ra
l
fl
ui
d
A
de
no
19
de
l
N
/A
N
/A
Y
es
S
in
gl
e
ag
en
t
5
P
os
t-
N
/A
N
/A
5
5d
on
,
9d
of
f
S
D
4
P
re
-
L
.
lu
ng
m
as
s
A
de
no
L
85
8R
N
on
e
N
/A
Y
es
W
it
h
ch
em
ot
he
ra
py
11
P
os
t-
L
.
pl
eu
ra
l
fl
ui
d
A
de
no
6
D
ai
ly
P
R
14
P
re
-
L
.
pl
eu
ra
A
de
no
L
85
8R
N
/A
N
/A
Y
es
S
in
gl
e
ag
en
t
4
P
os
t-
N
/A
N
/A
7
D
ai
ly
uP
R
6
P
re
-
R
.
lu
ng
m
as
s
A
de
no
19
de
l
T
79
0M
N
/A
N
o
S
in
gl
e
ag
en
t
2
P
os
t-
L
iv
er
le
si
on
b
C
ar
ci
no
m
a
8
D
ai
ly
uP
R
8
P
re
-
R
.
lu
ng
m
as
s
A
de
no
L
85
8R
N
on
e
N
/A
Y
es
W
it
h
ch
em
ot
he
ra
py
22
P
os
t-
R
.
lu
ng
m
as
s
A
de
no
P
at
ie
nt
4
la
ck
ed
a
co
nfi
rm
at
or
y
sc
an
du
e
to
pr
og
re
ss
io
n
of
di
se
as
e.
P
at
ie
nt
s
7
an
d
8
ha
d
P
R
at
th
ei
r
fi
rs
t
po
st
-X
L
64
7
sc
an
s;
ho
w
ev
er
,
th
ey
w
er
e
do
se
re
du
ce
d
se
co
nd
ar
y
to
to
xi
ci
ty
to
20
0
m
g
da
il
y
du
e
to
gr
ad
e
3
ra
sh
an
d
di
ar
rh
ea
,
re
sp
ec
ti
ve
ly
.
T
he
ir
su
bs
eq
ue
nt
sc
an
s
fa
il
ed
to
co
nfi
rm
P
R
.
a
P
os
t-
X
L
64
7
bi
op
sy
si
te
s
w
er
e
fr
om
le
si
on
s
th
at
w
er
e
in
vo
lv
ed
at
ba
se
li
ne
,
im
pr
ov
ed
or
st
ab
il
iz
ed
w
it
h
tr
ea
tm
en
t,
an
d
th
en
pr
og
re
ss
ed
.
b
O
nl
y
pa
ti
en
t
7
ha
d
a
ne
w
li
ve
r
m
et
as
ta
si
s
th
at
w
as
bi
op
si
ed
on
pr
og
re
ss
io
n,
al
th
ou
gh
ha
d
ha
d
li
ve
r
in
vo
lv
em
en
t
be
fo
re
st
ar
ti
ng
X
L
64
7.
P
R
,
pa
rt
ia
l
re
sp
on
se
;
uP
R
,
un
co
nfi
rm
ed
P
R
;
S
D
,
st
ab
le
di
se
as
e;
L
,
le
ft
;
R
,
ri
gh
t;
m
ut
n,
m
ut
at
io
n;
am
p,
am
pl
ifi
ca
ti
on
.
Chmielecki et al. Journal of Thoracic Oncology • Volume 7, Number 2, February 2012
Copyright © 2012 by the International Association for the Study of Lung Cancer436
pathologic review, there was no mention of any spindle-like
mesenchymal morphologic appearance that would represent
an epithelial to mesenchymal transition (EMT; data not
shown), or features of small cell carcinoma, ruling out his-
tological changes as a mechanism of resistance.28 One of
these samples underwent additional interrogation using mas-
sively parallel (454) sequencing (limit of detection 0.2%9);
the T790M mutant allele was still not detected (data not
shown). Tissue from only one patient was amenable to FISH
analysis for amplification of MET, a rarer mechanism of
acquired resistance23,24,28,29; the sample was negative.
At the discretion of the treating physicians, the eight
patients who came off study were subsequently immediately
treated with erlotinib, either as a single-agent (n  5) or in
combination with chemotherapy (n  3). Interestingly, three
of five patients treated with single-agent erlotinib derived
additional long-term benefit from the EGFR TKI, staying on
drug from 4 to 9 months (Table 1; Figures 1A, B). One patient
underwent tumor biopsy at the time of progression after
XL647, and the T790M mutation was not detected. Two of
these patients did not have tumor available for analysis after
disease progression, but their clinical courses suggested that
FIGURE 1. Representative case histories. A, Patient 2 was a 63-year-old white male former light smoker whose disease har-
bored an EGFR 19 del and displayed a partial response (PR) to XL647 (computed tomography [CT] scans of the chest shown
in top left and middle panels). After 9 months, the patient came off study after growth of a left lower lobe lung mass (arrowed)
and development of a left pleural effusion (top right panel). The patient underwent a video-assisted thorascopic surgery
(VATS) pleurodesis and was switched to single-agent erlotinib (bottom panels). The ground-glass opacities are likely due to the
pleurodesis. There was an 18% decrease in all lesions (by RECIST criteria) at the patient’s time of maximum response; the left
lower lobe lesion decreased by 24%. B, Patient 4 was a 68-year-old white female former light smoker whose disease harbored
a 19 del and displayed an unconfirmed PR to XL647 (four upper panels, CT scans). Therapy was discontinued after 5 months
when the patient developed leptomeningeal disease (left middle panel, axial T1 post magnetic resonance images). Tumor tis-
sue from this patient was not available at the time of developing resistance. However, following a switch to erlotinib single-
agent therapy, the leptomeningeal disease resolved (right middle panels). Concurrently, the patient’s right pleural effusion de-
creased (right lower panels, chest radiographs). C, Patient 7 was a 62-year-old Filipino female never smoker whose tumor
harbored a 19 del. She exhibited an unconfirmed PR on XL647 (left and middle panels, CT scans) but disease progressed in
the lung and liver after 5 months (right panels). Biopsy of the growing liver lesion revealed presence of the EGFR T790M
secondary mutation. Consistent with the presence of this mutation, the patient did not derive benefit from subsequent single-
agent erlotinib therapy.
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their disease lacked T790M. The patient whose disease har-
bored the T790M mutation progressed after 2 months on
subsequent erlotinib treatment (Figure 1C). The three patients
who received chemotherapy with erlotinib stayed on erlotinib
for 7, 11, and 22 months, respectively.
Derivation of EGFR-Mutant Cells with Acquired
Resistance to XL647
These intriguing clinical histories prompted us to ex-
amine properties of XL647 in preclinical models. Compared
with erlotinib, XL647 (Figure 2A) displayed similar growth
inhibitory effects against TKI-sensitive PC-9 lung adenocar-
cinoma cells, which harbor an exon 19 del, and H1975 cells,
which harbor an EGFR L858R TKI-sensitive mutation in
addition to a T790M TKI-resistant mutation. XL647 was
more potent than erlotinib at higher concentrations of drug
against H1975 cells (Figure 2B).
We next used a well-established protocol to develop
PC-9 cells with acquired resistance to XL647. We previously
reported the development of PC-9 cell lines with acquired
resistance to erlotinib or afatinib that were developed con-
currently; both were found to harbor the T790M mutation.9
After about 160 days of selection, PC-9 cells with acquired
resistance to XL647 (PC-9/XL-R cells) were able to prolif-
erate in concentrations 20 the IC50 of the parental cells
(Figure 3A). Analysis of protein lysates from PC-9/XL-R
cells demonstrated that phosphorylation of EGFR was unaf-
fected by addition of low or high concentrations of XL647
(Figure 3B). Direct sequencing of all the coding exons (2–28)
of EGFR revealed only the primary 19 del in DNA from
PC-9/XL-R cells (Figure 3C). More sensitive SNaPShot anal-
ysis also did not detect the T790M mutation (limit of detec-
tion 5%21; data not shown). Array comparative genomic
hybridization of DNA from PC-9/XL-R cells did not show
amplification of the MET kinase (Figure 3D). Assessment of
the phosphorylation state of 42 receptor tyrosine kinases
(RTKs) in the PC-9/XL-R cells in the presence of inhibitor
using phospho-RTK arrays revealed no obvious changes
compared with parental cells (Figure 3E). The exact mech-
anism of resistance of PC-9/XL-R cells remains to be
elucidated.
PC-9/XL-R Cells Remain Moderately Sensitive
to Erlotinib
To investigate the characteristics of the PC-9/XL-R
cells, we compared the mRNA expression profiles of PC-9/
XL-R versus corresponding erlotinib- (PC-9/ER) and afa-
tinib- (BIBW-2992) resistant (PC-9/BR) cells. Using super-
vised clustering algorithms, PC-9/XL-R cells clustered
completely separately from both sets of T790M-containing
cells, regardless of the absence or presence of drug (Figure
4A). A list of differentially expressed genes is available as
Supplemental Digital Content (http://links.lww.com/JTO/
A201). These data further support that PC-9/XL-R cells are
distinct from T790M-harboring PC-9/ER and PC-9/BR cells.
We next examined the sensitivity of PC-9/XL-R cells to
erlotinib. Similar to the observations in patients, these cells
remained intermediately sensitive to erlotinib (Figure 4B). By
contrast, PC-9 cells harboring the T790M mutation were
resistant to erlotinib (Figure 4B). Biochemical analysis of
PC-9/XL-R cells corroborated the growth inhibitory data and
showed decreased phosphorylation of EGFR and its down-
stream target, ERK, following treatment with high and low
doses of erlotinib (Figure 4C).
Selection for T790M-Harboring Clones in
Mixed Cell Populations May Differ between
XL647 and Erlotinib
To determine whether XL647 could select for cells har-
boring T790M mutations in mixed cell populations, we mixed
sensitive PC-9 cells (without T790M) with PC/BR clonal cells
harboring the T790M mutation at known proportions.9,14 Each
FIGURE 2. Activity of XL647
against EGFR-mutant lung cancer
cell lines. A, Chemical structures of
erlotinib and XL647. B, Growth in-
hibition assays comparing the ac-
tivity of XL647 with erlotinib
against PC-9 (19 del) and H1975
(L858R/T790M) cells.
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population was then treated with DMSO vehicle, erlotinib, or
XL647 for 7 days (Figure 5). As previously reported, vehicle-
treated cells harbored almost nondetectable levels of the T790M
allele at the end of the treatment cycle, likely due to faster
growth of the non-T790M-harboring sensitive cells.9,10 Treat-
ment with erlotinib selected for high levels of the T790M allele.
By contrast, the T790M allele peak height was not as high in
cells treated with XL647. These data are consistent with the
notion that XL647 may not be able to overcome T790M-
mediated resistance but that the selective pressure exerted by the
drug may be different than that of erlotinib.
Crystal Structure of XL647 within EGFR
To gain additional insights into XL647, the crystal
structures of both the Apo form of EGFR T790M at 2.7 Å
resolution and also its complex with XL647 at 2.3 Å resolu-
tion were solved. The binding mode of XL647 to EGFR-
T790M was similar to other agents with quinazoline cores
FIGURE 3. Derivation of PC-9 cells with acquired resistance to XL647. A, PC-9/XL-R cells grew in 20 the IC50 of parental
PC-9 cells, and were minimally affected by treatment with XL647 in growth inhibition assays. B, Immunoblotting studies show
decreased phosphorylation of EGFR in the presence of XL647 in parental but not resistant cells. C, Direct dideoxynucleotide
sequencing chromatograms from EGFR exons 19 (ex 19) and 20 (ex 20) show presence of the 19 del but no T790M mutation
in DNA from PC-9/XL-R cells. D, Array comparative genomic hybridization shows no amplification of MET on chromosome 7
in PC-9/XL-R cell line DNA. y axis: copy number gain/loss. E, Phospho-receptor tyrosine kinase (RTK) arrays on lysates from
PC-9 and PC-9/XL-R cells in the absence or presence of drug reveal no obvious differences in phospho-RTK status (1: pEGFR;
2: pHER3; 3: pFGFR3; 4: pIR; 5: pIGF1-R; 6: pDTK [TYRO3]).
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(Figure 6A). Comparison of the binding mode of XL647 in
EGFR-T790M versus XL647 in EGFR wildtype showed that
the substitution of T790 for the larger methionine residue
causes a slight shift of the aniline ring “forward” and away
from M790 (Figure 6B).
DISCUSSION
T790M-mediated resistance remains a major clinical
problem in NSCLC patients whose tumors harbor activating
mutations within EGFR. More potent “second-generation”
irreversible EGFR TKIs such as neratinib and afatinib have
FIGURE 4. PC-9/XL-R cells are distinct from T790M-harboring PC-9 cells. A, Heatmap generated via supervised cluster-
ing shows that mRNA expression profiles from PC-9 cells with acquired resistance to XL647 (PC-9/XL-R) are distinct from
T790M-harboring PC-9 cells developed through long-term culture in erlotinib (PC-9/ER) or afatinib (BIBW-2992) (PC-9/
BR). mRNA profiles were obtained from cells grown in the absence or presence of inhibitor. B, PC-9/XL-R cells retain
moderate sensitivity to erlotinib, compared with PC-9 cells harboring the T790M mutation. C, Immunoblotting studies
show decreased phosphorylation of EGFR and ERK at major signaling residues (tyrosine (Y) 1068 in EGFR, and threonine
(T) 202/tyrosine (Y) 204 in ERK) in the presence of erlotinib (E) in parental and PC-9/XL-R cells but not in PC-9 cells har-
boring the T790M mutation.
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been tested in early phase trials, but results have been disap-
pointing. Consistent with these clinical results, preclinical
models have shown that neratinib and afatinib still select for
T790M-mediated resistance in vitro,9,14 perhaps because they
still inhibit the drug-sensitive EGFR mutants at lower doses
than the T790M mutant. Analogously, the second-generation
EGFR TKI, XL647, showed minimal activity in a trial for
patients who progressed on gefitinib or erlotinib.19 These
studies collectively indicate that once patients’ tumors have
acquired the T790M mutation, single-agent EGFR TKIs with
greater sensitivity against drug-sensitive versus drug-resistant
mutants will not be clinically effective. In this setting, a more
promising approach may be dual targeting of EGFR with an
irreversible inhibitor plus an anti-EGFR antibody, a combi-
nation which recently showed a more than 40% response rate
in an phase IB/II trial.30 Alternatively, small molecule inhib-
itors with selectivity against the T790M mutant appear prom-
ising in preclinical models.31
Herein, we examined resistance that develops to XL647
in EGFR TKI-naive EGFR mutant lung cancer. From analo-
gous studies involving gefitinib or erlotinib, we have shown
that more than 50% of patients with acquired resistance
harbor T790M.22 Surprisingly, for XL647, only one of five
patients’ tumor samples available for analysis harbored the
T790M mutation. Two patients who did not have tumor
available for analysis also benefited from erlotinib, suggest-
ing that their disease also lacked T790M-mediated resistance.
Consistent with these clinical findings, PC-9 cells with ac-
quired resistance to XL647 did not harbor the T790M muta-
tion, displayed a distinct mRNA profile from PC-9 cells with
T790M-mediated resistance, and were moderately sensitive
to erlotinib in growth inhibition assays. These studies suggest
that it may be possible to find EGFR TKIs that do not
necessarily select for T790M-mediated resistance, even if
they have greater potency against drug-sensitive mutants.
This study has some limitations. First, only eight pa-
tients were studied, only five had tumor tissue acquired after
resistance developed, and some patients had only uncon-
firmed PRs. Although only one of these five samples har-
bored the T790M mutation, the numbers were too small to
make meaningful comparisons against those who developed
acquired resistance to gefitinib or erlotinib. In two cases
without available tissue at the time of progression (patients 4
and 6, Table 1), we cannot rule out that these tumors harbored
T790M and just progressed slowly while on erlotinib therapy
for 4 and 5 months, respectively.22 Second, patients were
treated with XL647 on different dosing schedules. We cannot
exclude that patients did not acquire the T790M mutation
because of related pharmacokinetic parameters; e.g., we have
shown that different dosing schedules can clearly influence
whether cells acquire T790M in vitro or not.9 However, in
modeling acquired resistance, we treated PC-9 cells with
erlotinib, afatinib, and XL647 in parallel, and only XL647-
treated cells did not develop T790M-mediated resistance.
FIGURE 5. Effect of TKI treatment on the number of
T790M-harboring cells in mixed cell populations. Using a
T790M-harboring clone (PC-9/BR, c1)9, cell populations
were mixed to have 0, 25, or 100% resistant cells. The base-
line panel shows forward sequence tracings from exon 20 of
EGFR (the underlined codon encodes T790). Cell popula-
tions were then treated with DMSO, XL647, or erlotinib at
the indicated doses for 7 days. Chromatograms display exon
20 forward sequences of EGFR from PC-9 cells treated with
different drugs (*ACG3ATG).
FIGURE 6. Crystal structure modeling of XL647 in the
EGFR ATP binding pocket. A, The binding mode of XL647 to
EGFR-T790M is largely as anticipated: the quinazoline core
forms a single hydrogen bond attachment to the protein
kinase “linker,” the solubilizing group extends toward sol-
vent, and the tri-halo aniline sits in the “aniline pocket” be-
tween the gatekeeper mutant methionine (T790M) and the
salt bridge. B, Comparison of the binding mode of XL647 in
EGFR-T790M (cyan carbons) versus XL647 in EGFR wildtype
(green carbons). Note that the substitution of T790 for the
larger methionine residue causes a slight shift of the aniline
ring “forward” and away from M790. The rotation of the
solubilizing group by 180° appears to be due to the pres-
ence of a new crystal lattice packing contact not seen in the
wild-type structure.
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This result suggests that dosing is not a critical issue. Third, three
of the patients studied received erlotinib plus chemotherapy after
progression on XL647. Thus, we were unable to assess whether
patients subsequently responded to single-agent erlotinib. Fi-
nally, we do not yet know how XL647 induces resistance. We
have excluded known mechanisms, including second-site muta-
tions, MET amplification, or a change in tumor morphology
(data not shown). Crystal structure analyses also were unreveal-
ing, as XL647 seems to bind in the EGFR ATP-binding pocket
in a manner similar to erlotinib. Whether concurrent inhibition
of other kinases such as ERBB2, KDR, and EPHB4 affects the
development of T790M-mediated resistance remains to be de-
termined. However, afatinib, which also inhibits ERBB2, and
vandetanib, which inhibits EGFR and VEGFR, both select for
T790M-mediated resistance in vitro,9,32 suggesting that inhibi-
tion of these kinases may not be relevant.
Despite these caveats, we present these clinical and
preclinical data because they raise the notion that different
EGFR TKIs may select for distinct mechanisms of resistance.
Thus, it may be possible to use noncross-resistant EGFR
TKIs sequentially to improve outcomes in patients with
EGFR-mutant lung cancer.
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